Bridging the Gap in Cancer-Related Stroke Management: Update on Therapeutic and Preventive Approaches

Sun, Ming-Yee; Bhaskar, Sonu

doi:10.3390/ijms24097981

Cited by 3 publications

(2 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous studies, cancer patients have a higher risk of stroke compared to the general population, and cancer-related stroke is a major factor in lowering the survival rate of cancer patients [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Some systematic reviews have also described that the relative risk of stroke is higher in cancer survivors than in the cancer-free population over an unspecified follow-up period [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

The Risk of Ischemic and Hemorrhagic Stroke in Head and Neck Cancer: A Longitudinal Cohort Study

Kim

2023

Cancers

View full text Add to dashboard Cite

Several studies have shown that head and neck cancer is associated with an increased risk of stroke incidence. However, investigations of the association between the two diseases based on a matching cohort dataset are still limited. Therefore, we identified the incidence and risk of stroke in patients with head and neck cancer using a nationwide population-based cohort dataset. A total of 5248 individuals without cancer and 1312 with cancer were enrolled from the dataset after a 4:1 propensity score matching. We found that the incidence of overall stroke (per 1000 person years) was 19.29 for those with head and neck cancer, consisting of 17.32 as ischemic type and 2.74 as hemorrhagic type. Additionally, patients with head and neck cancer had a significantly increased risk of overall and ischemic stroke development but not hemorrhagic stroke. Moreover, the risk of stroke development over time was relatively high within the first year after the diagnosis of head and neck cancer. However, in the subgroup analysis, oral cavity cancer survivors showed an increased risk of both ischemic and hemorrhagic strokes. Therefore, our nationwide population-based cohort study suggests that clinicians should closely monitor patients with head and neck cancers for the early detection of stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

The Risk of Ischemic and Hemorrhagic Stroke in Head and Neck Cancer: A Longitudinal Cohort Study

Kim

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Direct oral anticoagulants (DOACs) like rivaroxaban, dabigatran, edoxaban, and apixaban are widely used in clinical practice. They are prescribed for stroke prevention in patients with atrial fibrillation, the treatment of venous thromboembolism (VTE), prophylaxis against VTE in high-risk surgical procedures, the prevention of recurrent thromboembolism, and the management of thrombosis in cancer patients [ 1 , 2 , 3 , 4 ]. DOACs offer advantages such as convenience (oral administration without routine monitoring), predictable pharmacokinetics, and a reduced potential for drug interactions, making them favourable options for anticoagulation therapy compared to vitamin K antagonists in these clinical conditions [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Stability of Direct Oral Anticoagulants Concentrations in Blood Samples for Accessibility Expansion of Chromogenic Assays

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Direct oral anticoagulants (DOACs) are used for minimising the risk of thromboembolic events. In clinical practice, there is no need to measure DOAC concentration in the routine. Nevertheless, there are cases where such measurements are necessary, as the European Society of Cardiology’s guideline recommends. However, determining DOAC levels is not available for everyone due to chromogenic assay availability limitations from sample storage problems, as tests are performed only in a few healthcare settings. This study aimed to assess whether more applicable storage conditions could be used for transportation to provide chromogenic assays for outpatient healthcare and other hospitals’ practices. Materials and Methods: Chromogenic assays measuring anti-FXa (for rivaroxaban and edoxaban) and anti-FIIa (for dabigatran) were used. Concentrations were determined immediately after blood collection as baseline value: (1) after the storage of citrated whole blood in refrigerator (+2–8 °C); (2) of citrated plasma in refrigerator (+2–8 °C); and (3) of citrated frozen plasma (−20 °C) on the third and seventh days of storage. Acceptable change limits were considered stable if the deviation did not exceed ±20% of the baseline value. Results: The median (Cl 95%) baseline value of rivaroxaban was 168 (147–236) ng/mL; of dabigatran 139 (99–178) ng/mL; and of edoxaban—174 (135–259) ng/mL. The median deviation from a baseline value stored as citrate whole blood samples (+2–8 °C) was 5.4% and 3.4%; as citrated plasma (+2–8 °C) was 0.4% and −0.6%; and as citrated frozen plasma (−20 °C) was −0.2% and 0.2% on the third and seventh days of storage, respectively. Conclusions: Our data suggest that whole blood samples stored in a refrigerator, as well as citrated plasma samples stored in both the refrigerator and freezer, preserve DOAC concentration stable at +2–8 °C or −20 °C for up to 7 days, and are suitable for transportation, except for low-concentration samples.

show abstract

Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »

Pernod,

Cohen,

Mismetti

et al. 2024

La Revue de Médecine Interne

View full text Add to dashboard Cite

Bridging the Gap in Cancer-Related Stroke Management: Update on Therapeutic and Preventive Approaches

Cited by 3 publications

References 78 publications

The Risk of Ischemic and Hemorrhagic Stroke in Head and Neck Cancer: A Longitudinal Cohort Study

The Risk of Ischemic and Hemorrhagic Stroke in Head and Neck Cancer: A Longitudinal Cohort Study

Stability of Direct Oral Anticoagulants Concentrations in Blood Samples for Accessibility Expansion of Chromogenic Assays

Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »

Contact Info

Product

Resources

About